The key idea here is how lidocaine and amiodarone are used differently in ventricular tachycardia based on the situation and duration of therapy. Lidocaine, a sodium-channel blocker with preference for ischemic tissue, acts quickly to suppress arrhythmias that arise during acute ischemia. That makes it useful for acute ischemic VT where rapid control is needed. However, it isn’t typically used for long-term suppression because its efficacy wanes in nonischemic contexts and it carries risks of toxicity with prolonged use. Amiodarone has a broad antiarrhythmic profile, affecting multiple channels and receptors, which makes it effective both in the acute setting (for VT or VF) and as a durable, long-term option to prevent recurrence. Its downside is potential organ toxicity with chronic use, so it requires ongoing monitoring. Thus, the statement that lidocaine is useful for acute ischemic VT and amiodarone is useful for both acute VT/VF and long-term suppression best reflects how these drugs are applied in practice.